StockWatch
·
NAVIN FLUORINE INTERNATIONAL LIMITED-$ · QQ2 FY-2027 · THE CALL

Record growth & margin beat; CDMO at inflection point ahead

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsNAVINFLUORNavin Fluorine International Limited-$06 Nov 2026 · 6 min read
Verdict

Hold

confidence 7/10

Credibility

Grade A

Hit EBITDA guidance and beat margins. CDMO USD100M target achieved earlier than planned. Specialty Chemicals tracking to ₹350Cr+ target.

Short-term outlook

Optimistic

next 1–2 quarters

Long-term outlook

Very Optimistic

multi-year

Navin delivered a strong H1 with 57% revenue growth and 34.2% EBITDA margins (beating guided 32–33% ±1%), supported by HPP ref gas pricing, Specialty Chemicals momentum, and CDMO at inflection (USD100M run-rate target hit early). Long-term outlook is compelling: multiple molecule FDA readouts expected, Advanced Materials ₹90Cr capex to commercialize 4–5 products, and ₹350Cr+ Specialty Chemicals scale. Key near-term risk: geopolitical volatility and capex intensity (₹700–1,000Cr annually) will pressure FCF; hold until CDMO Phase 2 capex cadence clarifies and first FDA readouts land.

₹1190.7 Cr

Revenue · +57% YoY

₹269.2 Cr

Reported PAT · +81.5% YoY

Expanding

Margins · vs guidance: Corroborated

Did the claims hold up?

Management's claims vs. the numbers

EBITDA margins 34.2%, beating guidance range

MET

H1 EBITDA margin 34.2% vs prior guidance 32–33% ±1%

CDMO USD100M run-rate target, achieved earlier than initially planned

MET

Transcript confirms USD100M by FY27 on run-rate, now flagged as early

All three segments delivered sequential momentum

MET

HPP ref gas pricing advantage + volume, Specialty Chemicals growth, CDMO encouraged developments

Gross profit resilience despite cost inflation

MET

OPM 34.2% sustained via forex tailwind + pricing actions offsetting sourcing inflation

Earnings quality

What changed since the last call

Deltas vs. the prior call

CDMO scale-up pace

Upgrade

USD100M run-rate target hit in Q2 FY27 (earlier than planned). Phase 2 cGMP-4 capex (₹125 Cr) progressing for commissioning by end Q4 FY27.

Specialty Chemicals ramp

Upgrade

₹350Cr+ annual run-rate now targeted for FY27 end (vs. prior commentary of 'growth business'). PAR exceeding prior benchmarks on product mapping & molecule volume.

Soltice HFO contract

Upgrade

Extended 4-year contract now 11-year visibility to 2032; USD180M potential vs. prior USD58M annual run rate. Pricing mechanism pass-through; market dynamics (advanced cooling) underpinning upside.

Capex frame transparency

New

Defined ₹700–1,000 Cr annual capex envelope with multi-year line-of-sight (Phase 2, Advanced Materials, DRDO, etc.). Projects will be stage-gated; no formal guidance on final capex yet.

The Q&A

Analysts probed margin sustainability (inflation, sourcing), CDMO molecule timelines, Chemours project delays, and capex intensity. Management held firm: margins defended on operational efficiency + pricing power; CDMO delays are strategic (right process, not a miss); geopolitical risks flagged but navigable. Analysts broadly impressed; limited skepticism on execution risk.

The exchanges that mattered

Revenue bridge & segments — Sanjesh Jain, ICICI Securities

Answered

HPP: pricing advantage + ref gas volume. Specialty Chemicals: orchid & Corteva growth. CDMO: new molecule campaigns + Fermion base. All helping sequential ramp.

HFO contract extension — Rohit Nagraj, 360 ONE Capital

Answered

7-year avg was USD60–odd million; next 4 years USD45M (pricing pass-through mechanism). Extension adds USD180M potential; both volumes & pricing will increase over time.

CDMO Phase 2 & molecules — Ankur Periwal, Axis Capital

Answered

Phase 1 & 2 both Fermion-dedicated. 2 molecules in advanced stage; 1 China-approved, on fast track FDA. Others at label-expansion stage. 3–4 FDA readouts expected next 8–12 months.

Chemours specialty material (DRDO) — Archit Joshi, Nuvama Wealth

Answered

Delay is strategic (right process, not reactive). Pilot-scale to initial capacity involves different process routes. Already have orders for future quarters; dual-use potential (pharma ₹400Cr market + defense).

CDMO USD100M & capex plans — Arun Prasath, Avendus Spark

Answered

USD100M by FY27 on track. Phase 2 capex with full warehouse & ETP infra can reach cGMP-5 quickly. Peak annual revenue close to 3x capital (INR900–1,000Cr by FY28–29). Capex frame ₹700–1,000 Cr annually.

Margins durability — Sanjesh Jain, ICICI Securities (follow-up)

Answered

Forex tailwind + pricing actions offset sourcing inflation. Operating leverage (MPP debottlenecking, R32 ramp, AHF on play) also key. EBITDA 34% is sustainable on efficiency, not just pricing.

Specialty Chemicals PAR & capex — Sanjaya Satapathy, Ampersand Capital

Answered

No shift; building on what we have. Specialty Chemicals ₹350Cr+ by FY27 end. Advanced Materials 10–15% of pie by 2030 (₹90Cr capex to Q2 FY28). Next 5 years growth baked into capex plan.

HFO utilization & pipeline — Jason Soans, IDBI Capital

Answered

Utilization will improve. Demand upside from construction (cooling) & chillers sectors. HFO is premium product, greener. Expected demand to rise; some material also serving high-purity end use.

HFO pricing & patent dynamics — Ranjit, IIFL Capital

Answered

HFO is premium product (greener, 10% of global ref gas capacity). Patent expiry affects generics; Soltice is different application, evergreen product. Pricing power comes from end-use superiority, not patent alone.

Guidance

Forward guidance and management's confidence

FY27 EBITDA margins 32–33% ±1% (prior)

High

H1 delivered 34.2%, beating upper end. Management reaffirms long-term 30%+ sustainable; no formal change announced this call.

CDMO USD100M run-rate by FY27 end

High

Achieved in Q2 on run-rate basis, earlier than planned. Phase 2 capex (₹125 Cr) to scale capacity further.

EBITDA margin 34% long-term; near-term 'in same sort of range'

Medium

Management cautious on far-future due to geopolitical volatility. FY27 margins to stay in range of H1 (34.2%) for full year, with some normalization in H2.

Annual capex ₹700–1,000 Cr; H1 FY27 ₹300–310 Cr spent

High

Phase 2 cGMP-4 (₹125 Cr), Advanced Materials adoption (₹90 Cr), R32 capex, and other projects. Stage-gated; future capex to be announced as projects mature.

Risks the call surfaced

Ranked by how much they should concern a holder

Geopolitical volatility

Medium

Russia-Ukraine, Middle East tensions impact fluorine, HF, and refrigerant supply routes. Demand for industrial refrigerants sensitive to global capex cycles.

Customer concentration

Medium

Corteza & Soltice are material customer relationships for HPP ref gases. Loss of either could impact ₹400–500 Cr+ revenue.

Raw material inflation

Medium

HF, fluorspar, sulfuric acid prices have risen. If pricing power weakens (e.g., ref gas prices soften), margins could compress below 30% EBITDA.

Capex execution risk

Medium

₹700–1,000 Cr annual capex required through FY28. Delays in Phase 2 cGMP-4 or Advanced Materials adoption could defer growth & cash generation.

CDMO molecule FDA approval timing

Medium

3–4 FDA readouts expected in next 8–12 months. Delays or negative outcomes could slow CDMO revenue ramp beyond USD100M.

Management

Score 8/10. Clear and granular. Anish (CFO) provided segment-by-segment breakdown, capex frame, CDMO timelines, and margin drivers. Addressed evasive points (Chemours delay, HFO pricing) with candor; acknowledged geopolitical risks but conveyed navigability. Strong. Hit EBITDA guidance and beat margins. CDMO USD100M target achieved earlier than planned. Specialty Chemicals tracking ₹350Cr+ ambition. Capex commissioning (debottlenecking, R32) on schedule. No major misses flagged.

What to watch next
  • 1 · Q3 FY27

    HFC ref gas volumes from Corteva demand; R32 plant full commissioning

  • 2 · Q4 FY27

    MPP debottlenecking yield, specialty molecules campaign orders ramp

  • 3 · H2 FY27

    First FDA readouts on CDMO molecule pipeline (1–2 of 3–4 expected)

Key near-term risk: geopolitical volatility and capex intensity (₹700–1,000Cr annually) will pressure FCF; hold until CDMO Phase 2 capex cadence clarifies and first FDA readouts land.

Informational and educational content only. Not investment advice.